Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kosan Reprioritizes Pipeline As CEO Johnson Exits

This article was originally published in The Pink Sheet Daily

Executive Summary

Senior VP and Chief Business Officer Kim is appointed president, but the biotech has no plans to appoint a new CEO.

You may also be interested in...



Kosan Plans 37% Workforce Cut; Kim Rises To CEO

California biotech places most early research on hold to advance lead clinical candidates.

Kosan Plans 37% Workforce Cut; Kim Rises To CEO

California biotech places most early research on hold to advance lead clinical candidates.

Roche Backs Out Of Kosan Epothilone Deal

Kosan is “actively seeking” a new partner to begin Phase II trial for KOS-1584 after Roche unexpectedly terminates five-year collaboration.

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel